← All trials
NCT04790136
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 17, 2021
- Primary completion
- Apr 16, 2021
- Completion date
- May 12, 2021
- First posted
- Mar 10, 2021
- Last posted
- Jul 13, 2021
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SocraTec R&D GmbHLead sponsor
- SocraMetrics GmbHCollaborator
- Glatt Pharmaceutical Services GmbH & Co. KGCollaborator
- SocraTec R&D GmbHOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.